Argentina Breast Cancer Therapeutics Market Report 2022 to 2030

Argentina Breast Cancer Therapeutics Market Analysis

$ 3999

The Argentina breast cancer therapeutics market is projected to grow from $xx Bn in 2022 to $xx Bn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. An increase in research and development initiatives for oncology clinical trials is one of the major market drivers for Argentina's breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Tecsolpar Labs, Global Farm, and Bristol-Myers Squibb are some of the major market players in Argentina's breast cancer therapeutics market.

ID: IN10ARPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Argentina AUTHOR: Parul Choudhary

Buy Now

Argentina Breast Cancer Therapeutics Market Executive Analysis

The Argentina breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. The health spending per person in Argentina fell to 946 US dollars in 2021 from 1,128 US dollars the previous year, a 16.13% decrease. Argentina's health spending as a %age of GDP in 2021 was 9.5%. Despite significant fluctuations in recent years, Argentina's health spending as a %age of GDP generally increased from 2000 to 2021, reaching 9.5% in that year.

In Argentina, breast cancer is a serious health concern. Breast cancer is the most prevalent cancer among women in Argentina, making up around 25% of all female cancer cases, according to data from the International Agency for Research on Cancer. With 85.8 incidents per 100,000 women, Argentina has a relatively high incidence of breast cancer when compared to other nations in the region. The application of Boron Neutron Capture Therapy (BNCT) using immunoliposomes as boron carrier nano vehicles to target HER2 overexpressing cells is the focus of the Argentine BNCT Project proposal. Immunoliposomes marked with trastuzumab, a monoclonal antibody, attach specifically to breast cancer cells that overexpress the HER2 gene and would improve the selectivity and concentration of boron compounds in the tumor microenvironment.

Market Dynamics

Market Growth Drivers

An increase in research and development investment for novel therapeutics, frequent corporate social responsibilities (CSR) initiatives to raise breast cancer awareness, and mergers and acquisitions are the primary growth drivers for the Argentina breast cancer therapeutics market over the projected period.

Market Restraints

Since the average income in Argentina is quite low, many patients may find it difficult to afford more effective breast cancer therapies. The entry of new treatments to the market may be delayed by Argentina's lengthy and complicated approval process for new pharmaceuticals and treatments further hampering the growth of Argentina's breast cancer therapeutics market.

Competitive Landscape

Key Players

Drogueria Avenida (ARG)
Asofar (ARG)
Tecsolpar Labs (ARG)
Global Farm (ARG)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

All residents of Argentina are covered for breast cancer treatment under the country's universal healthcare system. The national government has prioritized breast cancer screening and treatment, and there are various programs in place to increase access to these services. The expense of breast cancer treatment, including surgery, radiation therapy, and chemotherapy, is also covered by the national health system. New and expensive treatments, though, might only be partially reimbursed by the public health system. Patients often pay a co-pay or co-insurance, which is a portion of the treatment's overall cost, for services covered by the national health system. The patient's income and the particular procedure will determine the co-pay or co-insurance amount.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.